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1. INTRODUCTION {#cam41840-sec-0001}
===============

Plasma cell myeloma (PCM) is a malignancy caused by clonal hyperplasia of plasma cells and accounts for 15% of all hematologic malignancies. PCM is the second most common hematologic malignancy. Although the efficacy of treatments for PCM and the prognosis of PCM patients have improved in recent decades due to the development of new drugs (proteasome inhibitors and immunomodulators) and the use of autologous stem cell transplantation (ASCT), PCM cannot be cured, and the median patient survival is only 3‐5 years. Multi‐parameter flow cytometry (MFC) for immunophenotyping plays an important role in the diagnosis, prognostic assessment, and minimal residual disease (MRD) of PCM.[1](#cam41840-bib-0001){ref-type="ref"}, [2](#cam41840-bib-0002){ref-type="ref"}, [3](#cam41840-bib-0003){ref-type="ref"}, [4](#cam41840-bib-0004){ref-type="ref"} CD117 is a tyrosine kinase receptor that is not expressed in normal plasma cells. Approximately 30% of malignant plasma cells express CD117. Some studies have revealed that CD117 expression on PCM cells is predictive of a good prognosis.[5](#cam41840-bib-0005){ref-type="ref"}, [6](#cam41840-bib-0006){ref-type="ref"}, [7](#cam41840-bib-0007){ref-type="ref"}, [8](#cam41840-bib-0008){ref-type="ref"}, [9](#cam41840-bib-0009){ref-type="ref"} CD81 is a transmembrane cell surface protein. Some studies have revealed that CD81 expression predicts a poor prognosis for PCM patients.[10](#cam41840-bib-0010){ref-type="ref"}, [11](#cam41840-bib-0011){ref-type="ref"}, [12](#cam41840-bib-0012){ref-type="ref"} In this study, CD117 and CD81 expression was analyzed in 131 patients who received initial treatment for PCM, and the relationship between CD117/CD81 expression and patient prognosis was further evaluated.

2. MATERIALS AND METHODS {#cam41840-sec-0002}
========================

2.1. Patient characteristics {#cam41840-sec-0003}
----------------------------

The case records of 131 patients with PCM were retrospectively reviewed. Samples were collected from patients who received initial treatment in the Affiliated Shengjing Hospital of China Medical University between January 2014 and May 2017. The medical records of the patients were complete at baseline, and included values for serum beta‐2‐microglobulin, albumin, calcium, hemoglobin, lactate dehydrogenase, serum creatinine concentrations, and the immunoglobulin type of monoclonal protein. PCM was diagnosed according to the diagnostic criteria of the International Myeloma Working Group and staged according to the International Staging System (ISS).[13](#cam41840-bib-0013){ref-type="ref"}, [14](#cam41840-bib-0014){ref-type="ref"} All the patients received either bortezomib‐ or thalidomide‐based chemotherapy. The study cohort included 79 males and 52 females with a median age of 62 years (range, 40‐85 years). The following types of PCM existed: IgG, 62 patients; IgA, 24 patients; IgD, nine patients; IgM, one patient; light chain, 30 patients; and non‐secretory, five patients. According to the ISS, 9, 72, and 50 patients were in PCM stages I‐III, respectively. The median duration of follow‐up was 10 months (range, 1‐38 months; Table [1](#cam41840-tbl-0001){ref-type="table"}).

###### 

Patient characteristics

  Parameter                                   N = 131
  ------------------------------------------- -------------------
  Median age, y (range)                       62 (40‐85)
  Gender                                      
  Male, n (%)                                 79 (60.31)
  Female, n (%)                               52 (39.69)
  Immunoglobulin type, n (%)                  
  IgG                                         62 (47.33)
  IgA                                         24 (18.32)
  IgM                                         1 (0.8)
  IgD                                         9 (6.9)
  Light chain only                            
  Kappa                                       12 (9.16)
  Lambda                                      18 (13.74)
  Non‐secretory, n (%)                        5 (3.82)
  Median beta‐2‐microglobulin, mg/L (range)   12.5 (1.2‐76.2)
  Median lactate dehydrogenase U/L (range)    164 (53‐913)
  Median albumin, g/dL (range)                3.3 (1.3‐4.9)
  Median calcium, mmol/L (range)              2.19 (1.67‐4.04)
  Median creatinine, µmol/lL (range)          101.7 (35‐1692.9)
  Median hemoglobin, g/dL (range)             7.9 (3.0‐15.2)
  ISS, n (%)                                  
  I                                           9 (6.87)
  II                                          72 (54.96)
  III                                         50 (38.17)
  Treatment, n (%)                            
  Bortezomib based                            47 (35.88)
  Thalidomide based                           84 (64.12)
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2.2. Detection {#cam41840-sec-0004}
--------------

### 2.2.1. Immunophenotyping {#cam41840-sec-0005}

Immunophenotyping was performed by flow cytometer (FACS Calibur; Becton Dickinson, San Diego, CA, USA) using mouse antihuman fluorescent monoclonal antibodies (fluorescein isothiocyanate \[FITC\], phycoerythrin \[PE\], peridinin‐chlorophyll‐protein \[Percp\], and allophycocyanin \[APC\]). The antibodies were purchased from Becton Dickinson, Beckman Coulter (Miami, FL, USA), Dako (Glostrup, Denmark), and BD Pharmingen (San Diego, CA, USA), respectively. Fresh bone marrow (3 mL) was treated with EDTA to prevent coagulation, and FITC/PE/Percp/APC was used for cell labeling as follows: cyKappa/cyLambda/CD45/CD38; CD19/CD138/CD45/CD38; CD16/CD56/CD45/CD38; CD13/CD117/CD45/CD38; CD28/CD27/CD45/CD38; CD5/CD81/CD45/CD38; HLA‐DR/CD200/CD45/CD38; and CD20/CD22/CD45/CD38. After incubation in the dark for 15 minutes, the bone marrow cells were hemolyzed by incubation with hemolysin (BD FACS lysing solution) for 10 minutes, and cyKappa/cyLambda was labeled in the cytoplasm. After incubation with antibodies, cells were subjected to flow cytometry. At least 50 000 cells were analyzed, and data were analyzed with CellQuest software (Becton Dickinson). CD38++/CD45 was used for gating, and then the antigen expression was analyzed. Negative expression was defined as a fluorescence intensity \<102, low expression was defined as a fluorescence intensity of 10^2^‐10^3^, and strong expression was defined as a fluorescence intensity of 10^3^‐10^4^. Positive expression was defined as\>20% of cells with showing antigen expression.

2.3. Statistical analysis {#cam41840-sec-0006}
-------------------------

CD81 expression, CD117 expression, and clinicopathologic characteristics were analyzed using the chi‐square test or t test. Progression‐free survival (PFS) was defined as duration from the start treatment to disease progression or patient death (regardless of the cause of death). PFS analysis events included disease progression, relapse, and patient death. Disease progression was diagnosed according to the diagnostic criteria of the IMWG.[13](#cam41840-bib-0013){ref-type="ref"} Overall survival (OS) was defined as the time from the date of diagnosis to the date of the patient\'s death. OS analysis events included only death. The loss of patients to follow‐up was treated as censored information. The Kaplan and Meier method and log‐rank test were used for survival analysis. A multivariate analysis was performed with a Cox proportional regression model. *P*‐values \<0.05 were considered statistically significant.

3. RESULTS {#cam41840-sec-0007}
==========

3.1. Patient characteristics and antigen expression {#cam41840-sec-0008}
---------------------------------------------------

All 131 patients (79 males and 52 females; median age = 62 years, range = 40‐85 years) met the study inclusion criteria. The abnormal plasma cells expressed CD138 and CD38++ in all of the patients; however, the expression of other antigens varied significantly. CD200, CD45dim, and CD56 positivity was demonstrated in 68.57%, 62.59%, and 59.54% of the patients, respectively, and CD81 and CD27 positivity was shown in 40.46% and 38.17% of the patients, respectively. Only 35.88% of the patients were positive for CD117, and only 2.29% and 8.40% of the patients were positive for B‐cell antigens (CD19 and CD20, respectively). The myeloid antigens CD13 and CD33 were expressed in 1.53% and 8.40% of the patients, respectively. Representative images for the flow cytometric analysis of CD81‐ and CD117‐positive plasma cell myeloma are shown in Figure [1](#cam41840-fig-0001){ref-type="fig"}. Next, the 131 patients were classified as CD117‐positive or CD117‐negative and CD81‐positive or CD81‐negative, and their clinical characteristics were further analyzed. The results showed that fewer CD117(+) patients were diagnosed with stage ISS‐III PCM and more CD81(+) patients were diagnosed with stage III PCM. In addition, the serum β2 microglobulin levels were lower in the CD117(+) patients (*P* = 0.000), higher in the CD81(+) patients (*P* = 0.000), and the serum calcium and creatinine levels were higher in the CD81(+) patients (*P* = 0.001; *P* = 0.001), but CD81 positivity was not related to any other clinical characteristics (Table [2](#cam41840-tbl-0002){ref-type="table"}).

![Flow cytometric analysis on plasma cell myeloma (black dots) is shown: A, CD38bri+ staining and CD45dim+ for gating; B, CD38bri+ staining and CD138+ for being identified as plasma cells; C‐D, The plasma cells show an expression profile of CD117 (positive) and CD81 (positive)](CAM4-7-5920-g001){#cam41840-fig-0001}

###### 

Baseline characteristics of newly diagnosed PCM patients based on expression of CD117 and CD81

  Parameter                                   CD117 expression     *P* value             CD81 expression                                 *P* value                                   
  ------------------------------------------- -------------------- --------------------- ----------------------------------------------- --------------------- --------------------- -----------------------------------------------
  Age ≥60                                     27                   44                    0.577                                           29                    42                    0.532
  Gender, male                                32                   47                    0.173                                           33                    46                    0.706
  ISS stage III                               11                   39                    0.009[\*](#cam41840-note-0002){ref-type="fn"}   27                    23                    0.013[\*](#cam41840-note-0002){ref-type="fn"}
  Monoclonal heavy chain                                                                                                                                                             
  IgG                                         27                   35                    0.599                                           26                    36                    0.369
  IgA                                         7                    17                    10                                              14                                          
  IgM                                         0                    1                     0                                               1                                           
  IgD                                         2                    7                     6                                               3                                           
  Light chain only                            10                   20                    8                                               22                                          
  BM plasma cell ≥5%                          33                   62                    0.658                                           41                    54                    0.306
  Median beta‐2‐microglobulin, mg/L (range)   4.91 (1.2‐25.9)      5.48 (1.9‐76.2)       0.000[\*](#cam41840-note-0002){ref-type="fn"}   5.47 (1.2‐76.2)       5.22 (1.9‐38.1)       0.000[\*](#cam41840-note-0002){ref-type="fn"}
  Median lactate dehydrogenase U/L (range)    154 (85‐913)         161 (53‐737)          0.266                                           189 (60‐737)          159 (53‐913)          0.199
  Median albumin, g/dL (range)                3.15 (1.3‐4.78)      3.35 (1.64‐4.94)      0.755                                           3.34 (1.3‐4.87)       3.27 (1.35‐4.94)      0.306
  Median calcium, mmol/L (range)              2.06 (1.67‐4.02)     2.22 (1.75‐4.04)      0.593                                           2.31 (1.67‐4.04)      2.16 (1.71‐3.1)       0.001[\*](#cam41840-note-0002){ref-type="fn"}
  Median creatinine, µmol/L (range)           88.2 (35.0‐1580.6)   110.2 (38.3‐1692.9)   0.268                                           102.7 (35.0‐1692.9)   101.7 (45.2‐1156.6)   0.001[\*](#cam41840-note-0002){ref-type="fn"}
  Median hemoglobin, g/dL (range)             7.9 (3.0‐15.2)       7.9 (4.0‐15.0)        0.819                                           7.8 (4.0‐15.2)        8.1 (3.0‐13.2)        0.515
  Therapeutic protocol                                                                                                                                                               
  Bortezomib‐based protocol                   17                   30                    0.958                                           16                    31                    0.263
  Thalidomide‐based protocol                  30                   54                    37                                              47                                          

*P* \< 0.05.
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3.2. Frequency of antigen expression and its impact on patient survival {#cam41840-sec-0009}
-----------------------------------------------------------------------

All of the patients received bortezomib‐ or thalidomide‐based chemotherapy, and there were no marked differences in the PFS and OS between the two groups (*P* \> 0.05). The PFS and OS were further analyzed based on antigens with high‐positive rates. The results showed that CD200, CD56, and CD27 had no influence on survival. CD117(+) patients had the longest median PFS (16 vs 12 months; *P* = 0.0355) and longest median OS (31 vs 20 months; *P* = 0.0016). CD81(+) patients had the shortest median PFS (9 vs 15 months; *P* = 0.0006) and shortest median OS (18 vs 28 months; *P* = 0.0018;). Based on CD117 and CD81 expression, patients were classified into the following three groups: good prognosis, CD117(+)CD81(−) group with a median PFS of 19 months and a median OS of 32 months; poor prognosis, CD117(−)CD81(+) group, with a median PFS of 9 months and a median OS of 16 months; and an intermediate prognosis subgroup, CD117(−)CD81(−)/CD117(+)CD81(+) group, with a median PFS of 12 months and a median OS of 24 months (Figure [2](#cam41840-fig-0002){ref-type="fig"}).

![Kaplan‐Meier analysis of progression‐free survival (PFS) and overall survival (OS) in group of patients with differential expression of  CD117 and CD81. (a) CD117(+)CD81(−) patients compared with CD117(−)CD81(−)/CD117(+)CD81(+) patients, (b) CD117(+)CD81(−) patients compared with CD117‐CD81+, (c) overall comparison. A, PFS of CD117(+) patients and CD117(−) patients. B, OS of CD117(+) patients and CD117(−) patients. C, PFS of CD81(+) patients and CD81(−) patients. D, OS of CD81(+) patients and CD81(−) patients. E, PFS of CD117(+)CD81(−), CD117(−)CD81(−)/CD117(+)CD81(+), and CD117(−)CD81(+) patients. F, OS of CD117(+)CD81(−), CD117(−)CD81(−)/CD117(+)CD81(+), and CD117(−) CD81(+) patients](CAM4-7-5920-g002){#cam41840-fig-0002}

3.3. Survival analysis {#cam41840-sec-0010}
----------------------

A Cox prognosis risk model was used for analyzing the relationship between common clinical characteristics, and PFS and OS. A univariate analysis showed that the following factors were closely associated with a short PFS (*P* \< 0.05): ISS stage III; beta‐2‐MG\>5.5 mg/L; CD117(−); CD81(+) (Table [3](#cam41840-tbl-0003){ref-type="table"}). Another univariate analysis indicated that the following factors were closely associated with OS (*P* \< 0.05): ISS stage III; age ≥60 years; beta‐2‐MG\>5.5 mg/L; creatinine\>176.8 µmol/L; CD117(−); CD81(+) (Table [4](#cam41840-tbl-0004){ref-type="table"}).Next, characteristics that were found to significantly affect the survival of PCM patients in the univariate analyses were further evaluated in a multivariate analysis. The results showed that age ≥60 years and CD81 positivity were independent factors that predicted a poor prognosis (shorter OS). CD117 positivity was an independent factor that predicted a good prognosis (longer OS; Table [4](#cam41840-tbl-0004){ref-type="table"}). ISS stage III and CD81 expression predicted a shorter PFS, while other factors showed no relationship with PFS (Table [3](#cam41840-tbl-0003){ref-type="table"}).

###### 

Univariate and multivariate Cox regression analyses of progression‐free survival

  Features                      *B*      Wald     HR (95% CI)           *P* value
  ----------------------------- -------- -------- --------------------- -----------------------------------------------
  Univariate Cox regression                                             
  ISS stage III                 0.829    7.932    2.291 (1.286‐4.080)   0.005[\*](#cam41840-note-0003){ref-type="fn"}
  Age ≥60 y                     0.454    3.529    1.575 (0.981‐2.529)   0.060
  Beta‐2‐MG\>5.5 mg/dL          0.829    7.923    2.291 (1.286‐4.080)   0.005[\*](#cam41840-note-0003){ref-type="fn"}
  Creatinine\>176.8 µmol/L      0.192    0.481    1.211 (0.705‐2.081)   0.488
  CD117(+)                      −0.523   3.992    0.593 (0.355‐0.990)   0.046[\*](#cam41840-note-0003){ref-type="fn"}
  CD81(+)                       0.779    10.335   2.179 (1.355‐3.505)   0.001[\*](#cam41840-note-0003){ref-type="fn"}
  Multivariate Cox regression                                           
  ISS stage III                 0.723    5.952    2.061 (1.153‐3.685)   0.015[\*](#cam41840-note-0003){ref-type="fn"}
  Beta‐2‐MG\>5.5 mg/dL          0.326    0.928    1.358 (0.714‐2.688)   0.335
  CD117(+)                      −0.318   1.374    0.727 (0.427‐1.239)   0.241
  CD81(+)                       0.582    5.299    1.790 (1.090‐2.940)   0.021[\*](#cam41840-note-0003){ref-type="fn"}

*P* \< 0.05.

John Wiley & Sons, Ltd

###### 

Univariate and multivariate Cox regression analyses for overall survival

  Features                      *B*      Wald     HR (95% CI)           *P* value
  ----------------------------- -------- -------- --------------------- -----------------------------------------------
  Univariate Cox regression                                             
  ISS stage III                 1.283    11.732   3.606 (1.731‐7.513)   0.001[\*](#cam41840-note-0004){ref-type="fn"}
  Age ≥60 y                     0.748    3.870    2.113 (1.003‐4.454)   0.049[\*](#cam41840-note-0004){ref-type="fn"}
  Beta‐2‐MG\>5.5 mg/dL          0.024    5.760    1.024 (1.004‐1.045)   0.016[\*](#cam41840-note-0004){ref-type="fn"}
  Creatinine\>176.8 µmol/L      0.605    2.636    1.831 (0.882‐3.800)   0.015[\*](#cam41840-note-0004){ref-type="fn"}
  CD117(+)                      −1.291   8.113    0.275 (0.113‐0.669)   0.004[\*](#cam41840-note-0004){ref-type="fn"}
  CD81(+)                       1.099    8.564    3.002 (1.438‐6.269)   0.003[\*](#cam41840-note-0004){ref-type="fn"}
  Multivariate Cox regression                                           
  ISS stage III                 0.747    2.715    2.111 (0.868‐5.133)   0.099
  Age ≥60 y                     0.833    4.539    2.301 (1.069‐4.954)   0.033[\*](#cam41840-note-0004){ref-type="fn"}
  Beta‐2‐MG\>5.5 mg/dL          0.019    0.568    1.019 (0.970‐1.070)   0.451
  Creatinine\>176.8 μmol/L      −0.001   0.607    0.999 (0.995‐1.002)   0.436
  CD117(+)                      −1.037   4.990    0.354 (0.143‐0.881)   0.025[\*](#cam41840-note-0004){ref-type="fn"}
  CD81(+)                       0.950    5.737    2.585 (1.188‐5.622)   0.017[\*](#cam41840-note-0004){ref-type="fn"}

*P* \< 0.05
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4. DISCUSSION {#cam41840-sec-0011}
=============

Flow cytometry is a common technique used in the routine diagnosis of PCM. Flow cytometry can accurately differentiate malignant plasma cells from normal plasma cells and also reveal the immunophenotype of PCM cells. Normal plasma cells express CD38bri, CD138, CD27, CD19, and CD81, but do not express CD56 and CD117; however, PCM cells express not only CD38bri and CD138, but also CD56, CD117, CD20, CD13, and CD33. Moreover, PCM cells do not express CD27 and CD81. It was previously reported that CD117 and CD81 positivity rates among patients receiving their initial treatment for PCM were 30% and 45%, respectively.[7](#cam41840-bib-0007){ref-type="ref"}, [11](#cam41840-bib-0011){ref-type="ref"}, [15](#cam41840-bib-0015){ref-type="ref"} In the present study, 35.88% of 131 patients tested were positive for CD117 expression, which was slightly higher than the previously reported,[7](#cam41840-bib-0007){ref-type="ref"}, [15](#cam41840-bib-0015){ref-type="ref"} and 40.46% of patients were CD81(+), which was slightly lower than that previously reported.[11](#cam41840-bib-0011){ref-type="ref"}

After grouping the patients according to CD117 and CD81 expression, more CD117(−) patients than CD117(+) patients were diagnosed with stage I or II PCM. When compared with the CD81(−) patients, more CD81(+) patients were diagnosed with stage III PCM, and those CD81(+) patients also had higher serum beta‐2‐microglobulin levels. While a total of 131 cases were enrolled in this study, but only 32 patients were sorted and FISH tested. The test results showed that CD117(−) patients had more IGH rearrangements and 1q21 gain than the CD117(+) patients, while CD81(+) patients had more 1q21 gain than the CD81(−) patients. Moreover, the CD117(−)CD81(+) group had more IGH rearrangements and 1q21 gain than either of the other two groups (Table [5](#cam41840-tbl-0005){ref-type="table"}). These characteristics appeared to affect the prognosis of PCM patients. While the prognostic value of CD117 in cancer remains controversial, there is evidence showing that CD117 might stimulate the proliferation of PCM cells[15](#cam41840-bib-0015){ref-type="ref"} and interfere with the effective proliferation of normal hematopoietic cells[16](#cam41840-bib-0016){ref-type="ref"}; however, most studies have reported that CD117 positivity predicts a good prognosis.[5](#cam41840-bib-0005){ref-type="ref"}, [6](#cam41840-bib-0006){ref-type="ref"}, [7](#cam41840-bib-0007){ref-type="ref"}, [8](#cam41840-bib-0008){ref-type="ref"}, [9](#cam41840-bib-0009){ref-type="ref"} Our results also revealed that CD117‐positive patients had longer PFS and OS than CD117(−) patients. This finding might be attributed to the normal plasma cells present in CD117(+) patients, as normal plasma cells inhibit malignant plasma cells from attacking normal precursor B cells, and thus help create conditions for a good prognosis.[16](#cam41840-bib-0016){ref-type="ref"}

###### 

Immunophenotype as grouped by FISH

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Chromosomal aberrancy\             P53 deletion   IgH rearrangement                               13q14.3 deletion   1q21 gain                                       RB1 deletion
  n = 32                                                                                                                                                               
  ---------------------------------- -------------- ----------------------------------------------- ------------------ ----------------------------------------------- --------------
  CD117(−)\                          2 (8.33%)      15 (62.5%)                                      10 (41.7%)         16 (66.7%)                                      10 (41.7%)
  n = 24                                                                                                                                                               

  CD117(+)\                          1 (12.5%)      1 (12.5%)                                       2 (25.0%)          2 (25.0%)                                       2 (25.0%)
  n = 8                                                                                                                                                                

  *P* value                          0.726          0.014[\*](#cam41840-note-0005){ref-type="fn"}   0.399              0.040[\*](#cam41840-note-0005){ref-type="fn"}   0.399

  CD81(−)\                           3 (14.3%)      8 (38.1%)                                       8 (38.1%)          9 (42.9%)                                       8 (38.1%)
  n = 21                                                                                                                                                               

  CD81(+)\                           0 (0)          8 (72.7%)                                       4 (36.4%)          9 (81.8%)                                       4 (36.4%)
  n = 11                                                                                                                                                               

  *P* value                          0.188          0.063                                           0.923              0.035[\*](#cam41840-note-0005){ref-type="fn"}   0.923

  CD117(+)CD81(−)\                   1 (14.3%)      0 (0)                                           2 (28.6%)          1 (14.3%)                                       2 (28.6%)
  n = 7                                                                                                                                                                

  CD117(−)CD81(+)\                   0 (0)          7 (70.0%)                                       4 (40.0%)          8 (80.0%)                                       4 (40.0%)
  n = 10                                                                                                                                                               

  CD117(−)CD81(−)/CD117(+)CD81(+)\   2 (13.3%)      9 (60.0%)                                       6 (40.0%)          9 (60.0%)                                       6 (40.0%)
  n = 15                                                                                                                                                               

  *P* value                          0.47           0.010[\*](#cam41840-note-0005){ref-type="fn"}   0.859              0.025[\*](#cam41840-note-0005){ref-type="fn"}   0.859
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*P* \< 0.05

John Wiley & Sons, Ltd

There is still controversy regarding the role of CD81 in the prognosis of PCM. CD81 is a transmembrane protein and plays an important role in synapse formation between B cells and T cells.[17](#cam41840-bib-0017){ref-type="ref"} CD81 can regulate CD19 expression in B lymphocytes and is also involved in cell growth, movement, signal transduction, and the homing of bone marrow cells.[18](#cam41840-bib-0018){ref-type="ref"} There is evidence showing that CD81 expression inhibits the migration and invasion of PCM cells, which suggests CD81 as an inhibitor of PCM metastasis.[19](#cam41840-bib-0019){ref-type="ref"} The findings of Paiva et al[20](#cam41840-bib-0020){ref-type="ref"} also support this conclusion. Specifically, Paiva et al[20](#cam41840-bib-0020){ref-type="ref"} speculated that down‐regulation of CD81 expression in PCM is one factor that promotes the release of PCM cells into the peripheral circulation. Moreover, Paiva et al[11](#cam41840-bib-0011){ref-type="ref"} also showed that CD81 expression is one of several factors that predict a poor prognosis for patients with smoldering PCM or symptomatic PCM. In recent years, Paiva et al[21](#cam41840-bib-0021){ref-type="ref"} reported that CD19(+)CD81(+) PCM cells are poorly differentiated clonal cells and predictive of a poor prognosis. Our present study results indicated that CD81(+) patients had a shorter PFS and OS, and more 1q21 gain than CD81(−) patients. It has been reported that 1q21 gain is closely associated with a poor prognosis.[22](#cam41840-bib-0022){ref-type="ref"}, [23](#cam41840-bib-0023){ref-type="ref"} In 2016, the International Myeloma Working Group defined 1q21 gain as a high‐risk genetic factor.[24](#cam41840-bib-0024){ref-type="ref"} The findings that led to that definition may help explain the poor prognosis of the CD81(+) patients. Our univariate analysis of possible risk factors revealed that BM plasma cells ≥5%, ISS stage III, age ≥60 years, beta‐2‐MG\>5.5 mg/L, creatinine\>176.8 µmol/L, CD117 negativity, and CD81 positivity could each affect the survival of PCM patients. Furthermore, our multivariate analysis of the above‐mentioned factors indicated that CD117 and CD81 were independent factors affecting the prognosis of PCM patients.

Our results showed that both CD117 and CD81 exert an important influence on the survival of PCM patients. The antigens expressed on plasma cells are diverse, and it is important to analyze the influence of two or more antigens simultaneously when seeking to establish a prognosis for PCM patients. In this study, both CD117 and CD81 were detected simultaneously, and the study patients were divided into the CD117(+)CD81(−), CD117(−)CD81(−)/CD117(+)CD81(+), and CD117(−)CD81(+) groups. Our results further confirmed that patients in the CD117(+)CD81(−) group had the best prognosis, while patients in the CD117(−)CD81(+) group had the least favorable prognosis.

Flow cytometry can not only be used for the rapid diagnosis of PCM, but also provides information for establishing a clinical prognosis. Our results indicate that CD117 positivity predicts a good prognosis for PCM patients, while CD81 positivity predicts a poor prognosis. We believe that these parameters can aid in establishing a prognosis for PCM patients in the clinic.
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